ArticleCellular & molecular immunology2019
Peripheral memory T cells specific for Arginase-1.
Article in Cellular & molecular immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- The roles of arginases and arginine in immunity.Nature reviews. Immunology · 2025Review
- Arginase-1-specific T cells target and modulate tumor-associated macrophages.Journal for immunotherapy of cancer · 2025Article
- Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition.International journal of molecular sciences · 2024Review
- Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.Oncoimmunology · 2024Article
- Regulated Arginine Metabolism in Immunopathogenesis of a Wide Range of Diseases: Is There a Way to Pass between Scylla and Charybdis?Current issues in molecular biology · 2023Review
- Tumor microenvironment antigens.Seminars in immunopathology · 2023Review
- An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.Frontiers in immunology · 2023Article
- Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.Frontiers in immunology · 2022Article
- Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression.Nutrients · 2021Review
- The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.Oncoimmunology · 2020Article
- Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.Cancer immunology, immunotherapy : CII · 2019Review
- Anti-regulatory T cells are natural regulatory effector T cells.Cell stress · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.